Citi Upgrades Hims & Hers on Novo Nordisk GLP-1 Pact
Citi upgraded Hims & Hers Health to neutral from sell after its Novo Nordisk GLP-1 drugs deal reduces key risks, and raised the price target to $24, signaling potential upside for the stock.
Tag
Hims And Hers Health
All articles tagged with #hims and hers health
Hims & Hers stock leaps on Novo Nordisk obesity-drug partnership talks via telehealth
Hims & Hers Health Inc. shares jumped in premarket trading after media reports that Novo Nordisk plans to sell obesity drugs through Hims & Hers' telehealth platform as part of a potential partnership between the two companies.
Bank of America Dumps Hims & Hers Amid Revenue Misses
Bank of America has lost confidence in the stock of Hims & Hers Health (HIMS), signaling a potential exit or reduced investment in the company.
Hims & Hers Surges 27% After Announcing Affordable GLP-1 Injections
Hims & Hers Health, a telehealth company, has surged to nearly $20 per share following a major product announcement involving GLP-1 agonists for weight loss. The company offers these products at significantly lower costs without requiring health insurance, attracting more consumers. With a rapidly growing customer base and diverse healthcare offerings, Hims & Hers is poised for substantial long-term growth, making it a compelling investment at its current price.